Yazar "Uysal, Sema" seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Airway inflammation and tiotropium treatment in stable COPD patients(Tubitak Scientific & Technological Research Council Turkey, 2014) Ozol, Duygu; Karamanli, Harun; Uysal, Sema; Yigitoglu, Muhammet Ramazan; Yildirim, ZekiBackground/aim: Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lung associated with progressive airflow limitation. The aim of this study is to assess the influence of tiotropium treatment on airway inflammation and symptoms in stable COPD patients. Materials and methods: Inflammatory markers were measured in the expired breath condensate fluid (EBC) before starting tiotropium treatment and at the end of the first month. Results: Twenty-two patients (81% men). with a mean age of 65.4 +/- 10.1 years completed the study. The mean nitrotyrosine and 8-isoprostane levels for oxidative stress markers in EBC before and after treatment were 4.5 +/- 2.3, 3.5 +/- 1.9 pg/mL (P = 0.06) and 7.3 +/- 10.8, 8.1 +/- 11.7 pg/mL (P = 0.28), respectively. The mean interleukin-6 and tumor necrosis factor-alpha levels for inflammation markers in EBC before and after treatment were 1.03 +/- 1.1, 0.77 +/- 0.8 pg/mL (P = 0.41) and 27.8 +/- 2.6, 29.2 +/- 5.7 pg/mL (P = 0.36) respectively. The mean symptom scores decreased significantly with tiotropium and a mean increase of 124.6 +/- 0.86 mL was observed in a lung function test (FEV1). Conclusion: Although a 4-week treatment with tiotropium did not modify any of the inflammatory or oxidative stress markers in EBC fluid, tiotropium treatment helps to control symptoms in COPD.Öğe Do the first, second and third trimester maternal serum hepcidin concentrations clarify obstetric complications?(Taylor & Francis Ltd, 2015) Simavli, Serap; Derbent, Aysel Uysal; Keskin, Esra Aktepe; Gumus, Ilknur Inegol; Uysal, Sema; Turhan, NilgunObjective: To evaluate whether first, second, and third-trimester maternal serum hepcidin levels are different in pregnancies with and without adverse pregnancy outcomes (APO). Methods: A 165 nullipar pregnant women were included in this prospective cohort study. Serum hepcidin, ferritin, IL-6, C-reactive protein (CRP) and Hb values were measured at 11-14, 24-28, and 30-34 weeks of gestation. The relation between these parameters and APO and neonatal outcomes were investigated. Preterm delivery, intrauterine growth restriction, preeclampsia, gestational hypertension and placental abruption were determined as adverse pregnancy outcomes. Results: The risk of APO was three times higher in women with high IL-6 levels in the second trimester. High hepcidin levels in the second trimester were associated with a 1.6 times increased risk of APO. Newborns of women with high IL-6 levels in the third trimester had a 1.6-fold increased risk of neonatal complications. High ferritin levels in the third trimester were associated with minimally increased risk of neonatal complications. Conclusions: Mean serum hepcidin levels were similar in all pregnant women, however, elevated second trimester serum hepcidin and IL-6 levels were associated with a higher risk of APO and high third trimester hepcidin, ferritin and IL-6 levels were associated with higher risk of neonatal complications.Öğe Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome(Edizioni Minerva Medica subscriptions.dept@minervamedica.it, 2014) Ademoğlu, Esranur; Berberoglu, Suha; Çarlioğlu, Ayşe Kargılı; Dellal, Fatma Dilek; Görar, Süheyla; Alphan, Ziynet; Uysal, SemaThe aim of this paper was to compare serum chemerin levels in nonobese and overweight/obese patients with polycystic ovary syndrome (PCOS) with lean controls. Methods. Seventy women with newly diagnosed or untreated PCOS and 38 age-matched nonobese healthy controls were enrolled in the present study. Participants with PCOS were categorized as nonobese (Body Mass Index [BMI] <25 kg/m2, N.=36) or overweight/obese (BMI 25-29.9 kg/m2 and ?30 kg/m2, respectively, N.=34). Anthropometric, metabolic and hormonal patterns, and serum chemerin were measured. Results. Serum chemerin tended to be higher in obese PCOS group than in nonobese PCOS women but did not reach statistical significance. Nonobese healthy controls had significantly lower chemerin levels than two PCOS groups (PcO.OOl). Fasting insulin (P<0.05) and homeostasis model assessment index (p<0.05) were significantly higher in obese women with PCOS than in other two groups. Also, these two parameters were higher in lean patients with PCOS than in healthy controls (p<0.05). In multiple linear regression analyses, chemerin was significantly associated with BMI (?-coefficient =0.336, p<0.01), and triglyceride (?-coefficient =0.298, p<0.05). Conclusion. Chemerin levels were significantly increased not only in obese PCOS women but also in nonobese PCOS women. The physiological significance of elevated serum chemerin in PCOS remains unclear. © 2016 Elsevier B.V., All rights reserved.Öğe Interaction of Metabolic Syndrome with Asthma in Postmenopausal Women: Role of Adipokines(Springer/Plenum Publishers, 2013) Aydin, Murat; Koca, Cemile; Ozol, Duygu; Uysal, Sema; Yildirim, Zeki; Kavakli, Havva Sahin; Yigitoglu, M. RamazanThe increasing prevalence of both asthma and obesity are major health problems. Recent studies established a possible link between obesity and asthma; however, the underlying mechanism is not clear. The aim of the study was to analyze the prevalence of metabolic syndrome in postmenopausal subjects with asthma and search the interactions between adipokines, metabolic syndrome, and asthma. A total of 45 female patients (57.5 +/- 13.9 years) with asthma and 30 healthy subjects (59.6 +/- 12.8 years) in postmenopausal status were enrolled in this study. For the diagnosis of metabolic syndrome, modified World Health Organization diagnostic criteria were used. Blood levels of glucose, lipid profile, HbA1c, insulin, CRP, leptin, adiponectin, tumor necrosis factor-alpha, interleukin (IL)-6, IL-8 and plasminogen activator inhibitor-1 (PAI-1) were measured. The mean body mass index was 29.6 +/- 5.4 for asthma patients and 28.2 +/- 5.3 for the control group. The incidence of metabolic syndrome was found as 26 % for both groups. Insulin resistance as calculated by homeostasis model assessment (HOMA-IR) and fasting insulin levels were significantly higher in asthma patients (p < 0.001 for both parameters). Leptin levels were significantly higher (p = 0.001) and adiponectin levels were lower (p = 0.029) in asthma patients compared to controls. We concluded that although incidence of obesity and metabolic syndrome was not higher in postmenopausal asthma patients than controls, there was an impairment of glucose metabolism and altered adipokine levels in asthma patients.Öğe Is There Any Relationship between Plasma Pentraxin 3 Levels and Gestational Diabetes Mellitus?(Karger, 2015) Yildirim, Melahat; Simavli, Serap Aynur; Derbent, Aysel Uysal; Kaygusuz, Ikbal; Uysal, SemaBackground: Pentraxin 3 (PTX3) is a novel vascular inflammatory marker which increases in vascular events such as diabetes mellitus. The aim of this study was to investigate the relationship between serum PTX3 levels and gestational diabetes mellitus (GDM). Methods: This prospective observational study was comprised of 88 pregnant women with singleton pregnancies. The subjects were classified into 3 groups according to their response to a 50-gram glucose challenge test (GCT) and a 100-gram oral glucose tolerance test: control group (n = 28), impaired glucose tolerance group (n = 30), and GDM group (n = 30). Serum PTX3 levels were measured to examine the relationship between GDM and GCT values. Results: Significant differences in PTX3 levels were observed among the 3 groups in the sample (F = 7.598; p = 0.001). The mean PTX3 value was found to be significantly higher in the GDM group (3.17 +/- 1.16 ng/ml) than in the control group (2.20 +/- 0.83 ng/ml; p = 0.001). A significant positive correlation between PTX3 and GCT values was detected (r = 0.289; p = 0.008). Conclusion: Maternal serum PTX3 levels were found to be significantly related to high blood glucose levels. This may be an indicator of vascular pathology in GDM around the time of an oral glucose tolerance test. (C) 2015 S. Karger AG, BaselÖğe Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion injury(Hospital Clinicas, Univ Sao Paulo, 2015) Nazli, Yunus; Colak, Necmettin; Alpay, Mehmet Fatih; Uysal, Sema; Uzunlar, Ali Kemal; Cakir, OmerOBJECTIVES: Prevention of the development of paraplegia during the repair of the damage caused by descending thoracic and thoracoabdominal aneurysms remains an important issue. Therefore, we investigated the protective effect of atorvastatin on ischemia-induced spinal cord injury in a rabbit model. METHOD: Thirty-two rabbits were divided into the following four equally sized groups: group I (control), group II (ischemia-reperfusion), group III (atorvastatin treatment) and group IV (atorvastatin withdrawal). Spinal cord ischemia was induced by clamping the aorta both below the left renal artery and above the iliac bifurcation. Seventy-two hours postoperatively, the motor function of the lower limbs of each animal was evaluated according to the Tarlov score. Spinal cord and blood samples were obtained for histopathological and biochemical analyses. RESULTS: All of the rabbits in group II exhibited severe neurological deficits. Atorvastatin treatment (groups III and IV) significantly reduced the level of motor dysfunction. No significant differences were observed between the motor function scores of groups III and IV at the evaluated time points. Light microscopic examination of spinal cord tissue samples obtained at the 72nd hour of reperfusion indicated greater tissue preservation in groups III and IV than in group II. CONCLUSION: This study demonstrates the considerable neuroprotective effect of atorvastatin on the neurological, biochemical and histopathological status of rabbits with ischemia-induced spinal cord injury. Moreover, the acute withdrawal of atorvastatin therapy following the induction of spinal cord ischemia did not increase the neuronal damage in this rabbit model.Öğe Polikistik overli hastalarda metformin tedavisinin antimüllerian hormon düzeylerine etkisi(2015) kamalak, zeynep; carlioglu, ayse; AKDENİZ, Derya; Uysal, Sema; GÜMÜŞ, İlknur İnegöl; ÖZTÜRK, Nilgün TURHANAmaç: Polikistik over sendromu, üretken çağdakikadınlarda sık görülen bir klinik durumdur.Hiperinsülinemi ve insülin direnci, hastalığınpatofizyolojisinde önemli bir antite olarak karşımıza çıkar.Çalışmamızın amacı; antimüllerian hormon (AMH)düzeylerinin metformin tedavisi sonrası değişiminiincele mekti.Yöntem : Rotterdam kriterlerine göre Polikistik over tanısıalan 84 hasta ve 28 sağlıklı gönüllü çalışmaya alındı.Hastaların yarısı (n=42) 1,7 gr/gün metformin tedavisialırken diğer 42 hasta tedavisiz izlendi. 6 aylık perioddansonra hastaların lab oratuar testleri karşılaştırıldı.Bulgular: AMH düzeyleri tedavi öncesi benzerdi.Metformin tedavisi sonrası tedavi alan PCOS hastaları vekontrol grubu AMH düzeyleri 6 aylık period sonrasındabenzer düzeylerde bulundu. Tedavi edilmeyenlere göre1.7 gr/gün metformin alan hastalarda AMH düzeyleribelirgin düşük olarak izlendi (p<0.001).Sonuç : AMH düzeyleri antral follikül volümü ve serumtestosteron düzeyleri ile korelasyon gösteren birparametredir. AMH ölçümünün, ovaryan yaşlanmayıdeğerlendirmede, poliki stik over tanısında ve tedavitakibinde yeri olduğu araştırılmıştır. AMH düzeylerininmetformin tedabisi sonrası düşmesi, metforminin PCOShastalarında kullanımını destekleyen bir veridir.Öğe Serum Levels of Visfatin and Possible Interaction with Iron Parameters in Gestational Diabetes Mellitus(Karger, 2013) Kaygusuz, Ikbal; Gumus, Ilknur Inegol; Yilmaz, Saynur; Simavli, Serap; Uysal, Sema; Derbent, Aysel Uysal; Gozdemir, ElifBackground/Aims: Visfatin is a novel adipokine with insulinomimetic properties that increases in diabetes. However, for gestational diabetes mellitus (GDM) there are conflicting reports. Recent studies have reported a positive association of serum ferritin concentrations with insulin resistance. Thus, we assessed serum levels of visfatin in pregnant women with varying degrees of glucose tolerance and investigated the possible interaction of visfatin with parameters of iron metabolism. Methods: Visfatin levels were measured at 24-28 weeks of gestation in 88 women who were divided into three groups according to their response to a 50-gram glucose challenge test and a 100-gram oral glucose tolerance test: control group (n = 28), impaired glucose tolerance (IGT) group (n = 30) and GDM group (n = 30). Results: Visfatin levels were significantly higher in the GDM and IGT group than in control (p < 0.001 for GDM vs. control, and p = 0.004 for IGT vs. control). Serum visfatin was significantly associated with serum ferritin, insulin, age, gravidity, and body mass index. In a linear regression model, the covariates explained only 17% of variability of serum visfatin concentration. Body mass index (p < 0.001) contributed independently to visfatin variance. Conclusion: Serum visfatin concentration is significantly higher in GDM and is correlated with ferritin levels. Copyright (C) 2013 S. Karger AG, BaselÖğe The Effect of Zofenopril on Pancreas, Kidney and Liver of Diabetic Rats(Turk Nefroloji Diyaliz Transplantasyon Dergisi, 2014) Carlioglu, Ayse; Akdeniz, Derya; Alkan, Rabia; Uz, Ebru; Haltas, Hacer; Turgut, Faruk; Uysal, SemaOBJECTIVE: Oxidative stress is responsible for some important complications of diabetes mellitus. Zofenopril, which has an antioxidant effect, may decrease the oxidative stress of the diabetic microenvironment. The aim of our study was to evaluate the effect of zofenopril in the liver, pancreas and kidney of alloxan- induced diabetic rats. MATERIAL and METHODS: Rats were divided into five groups: control group (n=6), rats treated with zonenopril (50 mg/kg/day, orally four weeks; n=6), rats exposed to alloxane (120 mg/kg single dose intraperitoneal injection, n=6), rats administered alloxan+ zofenopril (n=6) and rats administered insulin plus alloxan. RESULTS: After one month, we observed histological improvement in the kidneys but not in the pancreas and liver. CONCLUSION: In conclusion, zofenopril may be effective on the renal complications of diabetes mellitus.
